Overview

Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

Status:
Recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

A single center, Phase 1, open-label, fixed-sequence, drug-drug interaction study to evaluate the effect of multiple doses of Fluconazole, a CYP3A4 and CYP2C9 inhibitor, on the pharmacokinetics (PK) of CTP-543 in healthy subjects

Phase:

Phase 1

Details

Lead Sponsor:

Concert Pharmaceuticals

Treatments:

Fluconazole